Insider Buying: Delcath Systems, Inc. (NASDAQ:DCTH) COO Acquires 3,300 Shares of Stock

Delcath Systems, Inc. (NASDAQ:DCTHGet Rating) COO John Purpura purchased 3,300 shares of Delcath Systems stock in a transaction that occurred on Monday, May 16th. The stock was acquired at an average price of $4.61 per share, with a total value of $15,213.00. Following the transaction, the chief operating officer now owns 27,021 shares in the company, valued at $124,566.81. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website.

John Purpura also recently made the following trade(s):

  • On Monday, April 11th, John Purpura purchased 5,000 shares of Delcath Systems stock. The stock was acquired at an average price of $6.59 per share, with a total value of $32,950.00.

Delcath Systems stock traded up $0.08 during trading hours on Wednesday, reaching $4.54. 800 shares of the stock were exchanged, compared to its average volume of 30,044. The company has a quick ratio of 2.70, a current ratio of 2.93 and a debt-to-equity ratio of 2.55. Delcath Systems, Inc. has a 52-week low of $4.30 and a 52-week high of $13.50. The firm’s 50 day moving average is $6.09 and its 200 day moving average is $7.34.

Delcath Systems (NASDAQ:DCTHGet Rating) last announced its quarterly earnings data on Tuesday, May 10th. The company reported ($1.00) EPS for the quarter, missing analysts’ consensus estimates of ($0.88) by ($0.12). Delcath Systems had a negative return on equity of 246.07% and a negative net margin of 764.84%. During the same quarter in the previous year, the company posted ($1.04) EPS. On average, analysts forecast that Delcath Systems, Inc. will post -3.15 earnings per share for the current year.

A number of brokerages have commented on DCTH. StockNews.com began coverage on shares of Delcath Systems in a research report on Friday, May 13th. They set a “sell” rating for the company. Canaccord Genuity Group cut their price objective on shares of Delcath Systems from $24.00 to $20.00 and set a “buy” rating for the company in a research report on Monday, April 11th.

Institutional investors and hedge funds have recently made changes to their positions in the company. Dimensional Fund Advisors LP purchased a new position in shares of Delcath Systems in the 1st quarter valued at about $75,000. Virtu Financial LLC purchased a new position in shares of Delcath Systems in the 4th quarter valued at about $114,000. State Street Corp increased its holdings in shares of Delcath Systems by 70.3% in the 4th quarter. State Street Corp now owns 25,200 shares of the company’s stock valued at $195,000 after purchasing an additional 10,400 shares in the last quarter. Susquehanna International Group LLP purchased a new position in shares of Delcath Systems in the 4th quarter valued at about $209,000. Finally, Millennium Management LLC purchased a new position in shares of Delcath Systems in the 2nd quarter valued at about $405,000. Institutional investors and hedge funds own 21.93% of the company’s stock.

About Delcath Systems (Get Rating)

Delcath Systems, Inc, an interventional oncology company, focuses on the treatment of primary and metastatic liver cancers in the United States and Europe. The company's lead product candidate is HEPZATO KIT, a melphalan hydrochloride for injection/hepatic delivery system to administer high-dose chemotherapy to the liver while controlling systemic exposure and associated side effects.

Featured Articles

Insider Buying and Selling by Quarter for Delcath Systems (NASDAQ:DCTH)

Receive News & Ratings for Delcath Systems Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Delcath Systems and related companies with MarketBeat.com's FREE daily email newsletter.